A decrease in the number of tuberculosis patients in the Netherlands In 2019, the number of people with tuberculosis (TB) in the Netherlands decreased to 759. This is 5 per cent less than in 2018, when 797 were reported.
Population screening programmes temporarily on hold Due to the novel coronavirus (COVID-19) outbreak, the health care capacity in the Netherlands is expected to come under severe pressure in the coming period.
Interim injunction decision Nitrogen In an interim injunction proceeding between Mesdag Zuivelfonds, Stichting Stikstofclaim and RIVM, the court has ruled that RIVM must decide on the availability and disclosure of data before 1 Janua
How to distinguish a dual user from an exclusive e-cigarette user RIVM and Maastricht University have identified a combination of factors that can be used to distinguish between exclusive e-cigarette users (vapers) on the one hand and people who smoke both regula
Can you solve a medical mystery? During World Antibiotic Awareness Week 2019, RIVM has set up an escape room in one of busiest shopping malls in the Netherlands.
Exploratory RIVM calculations of nitrogen measures The Dutch government announced its plans for the first steps in tackling the nitrogen deposition issue.
Environmental radioactivity in the Netherlands : Results in 2017 RIVM reports annually on the level of radioactivity that occurs under normal circumstances in the environment and food.
Openness about nitrogen There is concern about the current approach to nitrogen and the proposed measures; these concerns have been expressed in Dutch society as a whole and amongst farmers in particular.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Slightly more tuberculosis patients in the Netherlands The key figures of the National Institute for Public Health and the Environment (RIVM) show that in 2018 there were 806 TB patients in the Netherlands. This is 3 percent more than in 2017 (784).